Maleki Arash, Lamba Neerav, Ma Lina, Lee Stacey, Schmidt Alexander, Foster C Stephen
Massachusetts Eye Research and Surgery Institution; Ocular Immunology and Uveitis Foundation, Waltham.
Massachusetts Eye Research and Surgery Institution; Ocular Immunology and Uveitis Foundation, Waltham; Harvard Medical School, Boston, MA, USA.
Clin Ophthalmol. 2017 Feb 17;11:377-385. doi: 10.2147/OPTH.S120162. eCollection 2017.
To examine the efficacy of rituximab as a monotherapy or in combination therapy for the treatment of patients with non-paraneoplastic autoimmune retinopathy.
Twelve eyes of six patients with non-paraneoplastic autoimmune retinopathy who were treated with rituximab and had at least 6 months of follow-up were included. Demographic data, clinical data, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic nerve autoantibody bands were collected from the Massachusetts Eye Research and Surgery Institution database between September 2010 and January 2015. Changes in visual acuity, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic nerve autoantibody bands from the initial visit to the most recent visit were examined.
From the initial visit to the last visit, visual acuity was stable in eight (66.7%) eyes. Visual field was stable in six (50%) eyes and improved in two (16.7%) eyes. Electroretinography was stable or improved in eight (66.7%) eyes. The average number of anti-retinal and anti-optic nerve antibody bands was reduced.
Stabilization and/or improvement of visual acuity, visual field parameters, and electroretinography parameters were observed in a high number of patients (75%) on rituximab, as a monotherapy (one patient) or in combination therapy.
研究利妥昔单抗单药治疗或联合治疗非副肿瘤性自身免疫性视网膜病变患者的疗效。
纳入6例接受利妥昔单抗治疗且随访至少6个月的非副肿瘤性自身免疫性视网膜病变患者的12只眼。从2010年9月至2015年1月期间的马萨诸塞州眼研究与手术机构数据库中收集人口统计学数据、临床数据、视野参数、视网膜电图参数以及抗视网膜和抗视神经自身抗体条带。检查从初次就诊到最近一次就诊时视力、视野参数、视网膜电图参数以及抗视网膜和抗视神经自身抗体条带的变化。
从初次就诊到最后一次就诊，8只眼（66.7%）的视力稳定。6只眼（50%）的视野稳定，2只眼（16.7%）的视野改善。8只眼（66.7%）的视网膜电图稳定或改善。抗视网膜和抗视神经抗体条带的平均数量减少。
在接受利妥昔单抗单药治疗（1例患者）或联合治疗的大量患者（75%）中，观察到视力、视野参数和视网膜电图参数稳定和/或改善。
